Abstract
Background
Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Saharan Africa. The drug shows high variability in drug exposure in previous pharmacokinetic studies. This study aims to build a population pharmacokinetic (PopPK) model to identify and quantify the possible sources of the variability of IVM exposure after a single–oral dose in LF–infected subjects and healthy individuals.
Methodology / Principal findings
In this analysis, 724 samples were collected from treatment–naïve Wuchereria bancrofti–infected (n = 32) and uninfected (n = 24) adults living in Côte d’Ivoire who had received one dose of IVM as a part of triple–drug therapy. PopPK analysis was conducted using Phoenix NLME 8.3 software. The Monte Carlo simulation based on the final model was performed to simulate drug exposure among different dosing groups (200 μg/kg, 18 mg, and 36 mg). A two–compartment model with zero–order dose input into the absorption compartment with a lag time function followed by first–order absorption and linear elimination best described the IVM’s pharmacokinetic (PK) parameters. The final model identifies that the PK parameters of IVM are not affected by LF infection. Sex was a significant covariate on the peripheral volume of distribution (Vp/F, 53% lower in men than in women). IVM drug exposure shows linear pharmacokinetic behavior among the simulated dosing groups with similar drug exposure based on sex.
Conclusion/Significance
We have developed a PopPk model to describe and identify possible sources of the variability of IVM exposure. To our knowledge, this is the first PopPK study of IVM in patients with LF.
Trial registration
NCT02845713; NCT03664063
Funder
Bill and Melinda Gates Foundation
Publisher
Public Library of Science (PLoS)
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference32 articles.
1. Lymphatic filariasis: diagnosis and pathogenesis. WHO expert committee on filariasis;Bull World Health Organ,1993
2. Summary of global update on preventive chemotherapy implementation in 2016: crossing the billion.;Wkly Epidemiol Rec,2017
3. Global programme to eliminate lymphatic filariasis: the processes underlying programme success.;K Ichimori;PLoS Negl Trop Dis,2014
4. The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling;Gates Open Res,2019
5. Effectiveness of a triple–drug regimen for global elimination of lymphatic filariasis: a modelling study;MA Irvine;Lancet Infect Dis,2017